[Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
To evaluate JAK2V617F point mutation in patients with polycythemia vera (PV) and its clinical significance, the point mutation was detected by allele specific polymerase chain reaction (AS-PCR), and the clinical and laboratory features of 50 PV patients with JAK2V617F positive and negative mutations were analyzed and compared each other. The results showed that among 50 patients, 31 patients (62.0%) had JAK2V617F point mutation; 12 patients (24.0%) showed thrombosis and microvascular disturbances; 3 patients had chromosome karyotype abnormalities. As compared with negative mutation group, the age and leukocyte count in patients with JAK2V617F point mutation were older (57.5 +/- 10.0 vs 45.6 +/- 14.9, p < 0.05) and higher (16.2 +/- 6.7 vs 9.0 +/- 5.2, p < 0.05) respectively. It is concluded that the frequency of the JAK2V617F point mutation is 62.0% in PV patients, the age and leukocyte count of patients with JAK2V617F point mutation are older and higher respectively than those in negative mutation group.
Shen
Yun-Feng
YF
Department of Hematology, Wuxi First Affiliated Hospital of Nanjing Medical University, Wuxi 214023, China. yfshen21cn@yahoo.com.cn
Xia
Jun
J
Lu
Mi-Ze
MZ
Jiang
Yuan-Qiang
YQ
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011087:Polycythemia Vera / Q000235:genetics*; D055815:Young Adult
C507924:JAK2 protein, human; D053614:Janus Kinase 2